POVETACICEPT DEMONSTRATES ENHANCED SERUM EXPOSURE AND TISSUE DISTRIBUTION RELATIVE TO WILD-TYPE TACI-Fc MOLECULES

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

Abstract Title *

POVETACICEPT DEMONSTRATES ENHANCED SERUM EXPOSURE AND TISSUE DISTRIBUTION RELATIVE TO WILD-TYPE TACI-Fc MOLECULES

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Stacey Dillon Stacey_Dillon@vrtx.com Vertex Pharmaceuticals Research Seattle United States -

Co-author 2

Shyamesh Kumar Shyamesh_Kumar@vrtx.com Vertex Pharmaceuticals Preclinical Sciences Boston United States *

Co-author 3

Phammela Abarzua Phammela_Abarzua@vrtx.com Vertex Pharmaceuticals Preclinical Sciences Boston United States -

Co-author 4

Carly Hennessey Carly_Hennessey@vrtx.com Vertex Pharmaceuticals Research Seattle United States -

Co-author 5

Kristin Bouve Kristin_Bouve@vrtx.com Vertex Pharmaceuticals Preclinical Sciences Boston United States -

Co-author 6

Qing Nie Qing_Nie@vrtx.com Vertex Pharmaceuticals Preclinical Sciences Boston United States -

Co-author 7

Chelsea Gudgeon Chelsea_Gudgeon@vrtx.com Vertex Pharmaceuticals Research Seattle United States -

Co-author 8

Michelle Seaberg Michelle_Seaberg@vrtx.com Vertex Pharmaceuticals Preclinical Sciences Seattle United States -

Co-author 9

Lara Parr Lara_Parr@vrtx.com Vertex Pharmaceuticals Preclinical Sciences Seattle United States -

Co-author 10

Madison Miller Madison_Miller@vrtx.com Vertex Pharmaceuticals Preclinical Sciences Seattle United States -

Co-author 11

Allison Chunyk Allison_Chunyk@vrtx.com Vertex Pharmaceuticals Preclinical Sciences Seattle United States -

Co-author 12

Stanford Peng Stanford_Peng@vrtx.com Vertex Pharmaceuticals Research Seattle United States -

Co-author 13

Lawrence Evans Lawrence_Evans@vrtx.com Vertex Pharmaceuticals Research Seattle United States -

Co-author 14

Co-author 15